Send to

Choose Destination
Lung Cancer. 2005 Sep;49(3):413-5.

EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.

Author information

Division of Hematology and Oncology, Department of Internal Medicine, Mackay Memorial Hospital, CMU, Taipei, Taiwan.


EGFR mutations have been shown to correlate with the clinical responsiveness to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). The detection of EGFR mutations in non-small cell lung cancer (NSCLC) is important from the perspective of targeted anticancer therapy. We report the first case showing that the status of EGFR mutations can be successfully determined in malignant pleural effusion of NSCLC using polymerase chain reaction (PCR) technique, and correlated to the clinical responsiveness to gefitinib, an EGFR-TKI. This case demonstrated the importance of molecular cytology in the era of targeted therapy.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center